Antimicrobial Resistance Diagnostics Markets 2027–2031

Antimicrobial Resistance Diagnostics Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027–2031

Global forecasts by pathogen, technology, infection site, purpose and product, for 14 countries and regions, with 40 company profiles.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Resistance testing is finally getting fast. Culture and phenotypic susceptibility testing still make up most of the market, but rapid AST, molecular tests and sequencing take most of the new spending as hospitals try to give the right antibiotic sooner. The market grows from $3,460 million in 2026 to $5,400 million in 2031, at 9.3% a year. The industry is also consolidating hard: several rapid-test pioneers have failed, and the survivors now sit inside larger companies with a sales force and an installed base.

Market Size 2026: USD $3.46B   Market Size 2031: USD $5.4B   CAGR: 9.3%

Situation Analysis: what is really happening

• Rapid AST is becoming routine. The FDA cleared Q-linea's expanded ASTar menu of 215 bug–drug combinations and a larger bioMérieux VITEK REVEAL menu. Rapid phenotypic AST grows from $190.3 million to $567.0 million, at 24.4% a year.
• The shake-out is under way. Bruker bought the former Accelerate Diagnostics rapid-AST business, T2 Biosystems liquidated, and OpGen left diagnostics as CapForce.
• The big players are reshaping. Waters took over BD's microbiology business, including Phoenix, BACTEC and Kiestra, and Hologic was taken private by Blackstone and TPG.
• Gram-negatives lead the growth. Carbapenem-resistant Enterobacterales (CRE) is the fastest-growing pathogen group at 14.1% a year, and CRE and ESBL testing together rise from $934.2 million to $1,728.0 million.
• Sepsis is the largest battleground. Bloodstream infection and sepsis testing grows from $986.1 million to $1,674.0 million, at 11.2% a year.
• Policy is backing diagnostics. The World Health Assembly adopted the Global Action Plan on AMR for 2026–2036, industry launched the GO-Dx access compact at the G7, and CARB-X made neonatal sepsis diagnostics a funding priority.

Company Analysis: who is positioned, who is exposed

• bioMérieux: The leader in susceptibility testing, blood culture and syndromic panels, now expanding VITEK REVEAL rapid AST while its respiratory panel sales fall.
• Waters (formerly BD Diagnostic Solutions): Owns Phoenix, BACTEC, Kiestra and BD MAX after February 2026 and must keep customers through the integration.
• Bruker: The MALDI-TOF leader, moving into rapid AST with the former Accelerate technology.
• Danaher (Beckman Coulter and Cepheid): MicroScan AST and the Xpert resistance tests give it both phenotypic and molecular positions.
• Q-linea, Pattern Bioscience, Selux and Gradientech: Rapid-AST challengers with strong technology but small installed bases and funding risk.
• Karius, Illumina and Oxford Nanopore: Bring sequencing and metagenomics to resistance detection.

In all, 40 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Questions this report answers

• How fast will rapid AST, PCR, syndromic panels and sequencing replace culture-based testing?
• Which resistant pathogens will drive the most new testing, and why?
• Who survives the shake-out among rapid-AST developers, and who is buying them?
• How will stewardship rules, breakpoint updates and new antibiotics change testing demand?
• What do the WHO Global Action Plan, CARB-X and national AMR plans mean for diagnostics?
• How large is each country market, and how fast are China and India growing?

What's inside

• 297 pages, 23 chapters, 68 tables and 54 figures
• Forecasts for 2027–2031 from a 2026 base year, by pathogen, technology, infection site, purpose and product, for 14 countries and regions
• Phenotypic and rapid AST, molecular resistance testing, syndromic panels and NGS, and a chapter on each priority pathogen
• Sepsis and stewardship, infection control and One Health surveillance, regulation, reimbursement and AMR policy, and China, India and emerging markets
• 10 market-moving developments from 2025 and 2026, SWOT, Porter's Five Forces and strategic recommendations
• 40 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Diagnostic companies and business development teams: size each technology and pathogen market and track the consolidation.
• Microbiology laboratory and hospital leaders: plan the move to faster susceptibility testing.
• Investors and analysts: judge which rapid-test companies can reach scale.
• Public health and AMR programmes: plan surveillance and diagnostic access.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.